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Prognosis of renal function after kidney biopsy in renal transplanta-
tion. M. Zeiler, Mi. Mihatsch, and G. Thiel, Kantonsspital Base!, Institut für
Pathologie und Abteilung für Nephro!ogie, Base!, Switzerland. Rejection is
the most limiting factor in long-term kidney transplant outcome despite
optimal clinical treatment. Clinical parameters in correlation with histo-
logical features were evaluated retrospectively. Exclusively initial allograft
biopsies were considered. Biopsy timepoint after transplantation (Bx-time,
in days) was noted. The following histological categories were analyzed:
(a) vascular rejection (VR); (b) glomerulonephritis (GN); (c) aggressive
interstitial-cellular rejection (ICR); and (d) acute tubular necrosis (ATN).
Other morphologic features were not evaluated. Plasma creatinine levels
at time of biopsy (Bx-crea, in jzmol/liter) were correlated with those 12
months post-biopsy. Endpoints were the absolute (-crea) and percent
(%-crea) change of plasma creatinine and the return to dialysis.
Schachinger, B. Martina, T. Dieter!e, C. HaberthOr, P. Huber, A. Bock, R.
Ritz, and K. Gyr, Medizinische Universitats-Po!iklinik, DIM, Universitats-
kliniken, Base!, Switzerland. Patients with primary arterial hypertension
have been found to show blunted angiotensin II (A2) responsivity of the
renal vasculature during high salt intake (non-modulators). We hypothe-
sized that pharmacological suppression of A2 formation would reveal
similar results in normotensive offspring of hypertensives. Therefore, RBF
(C-PAH) was assessed in 33 healthy men [16 with positive family history
(FH+) for hypertension (BP: 120 7/66 6 mm Hg, age: 25 3 years)
and 17 matched control subjects without family history (FH—) for
hypertension (BP: 118 8/61 5 mm Hg, age: 25 5 years.)] during
baseline (BL), acute intravenous application of enalaprilat (acute ACEI)
and constant infusion of subpressor A2 (1 ng/kg/min) before and after
chronic ACE-inhibition (cACET) by 1 week oral enalapril (30 mg daily).
VR
(N=171)
GN
(N=45)
ICR
(N=70)
ATN
(N=25)
Bx-time 243 43, 34 494 68, 429 107 23, 36 46 25, 13
Bx-erea 407 26, 238 213 28, 162 216 15, 189 714 71, 999
%-crea —12 6, —16 —3 5, —2 —10 5, 16 —65 7, —84
-crea —106 30, —24 —35 24, —4 —34 11, —27 —576 80, —829
Dialysis 44% (N = 75)13% (N 6) 10% (N=7) 12% (N = 3)
Mean SEM, median.
In the group of patients showing VR Bx-crea was significantly higher in
patients on dialysis after one year (571 41 imol/liter) than in those with
a functioning graft (279 27 jzmol/liter). Return to dialysis was signifi-
cantly more frequent in patients presenting VR than in any other group.
In conclusion, early biopsy is recommended in every case of renal function
deterioration in order to prevent extensive, therapeutically irresponsive
tissue damage.
Effect of salt and water diuresis on urine endothelin-1 in humans. M.
Zeiler, B.-M Loffler, H.A. Bock, and G. Thiel, Kantonsspital Base!, Abtei-
lung f-fir Nephrologie, F. Hoffinann-La Roche, Base!, Switzerland. Differ-
ences in urine endothelin-1 excretion (uET-1/min) depending on the type
of urine flow stimulation were reported in humans. Cell culture studies
have shown an osmolality dependent ET-1 production. We therefore
investigated uET-1/min in different states of urine osmolality provoked by
glucose (water diuresis) or NaCl (salt diuresis) infusion. In six healthy
subjects uET-1/min was measured during overnight urine collection and
during water diuresis stimulated by glucose 5% infusion (15 mI/kg for 90
minutes). NaCI 0.9% infusion (20 ml/kg for 90 minutes) was given on a
separate day to provoke salt diuresis. For each type of infusion six
measurements were achieved before and 12 during infusion. uET-1/min
correlated significantly with urine flow in both states of diuresis (P < 0.01).
No difference in the slope of the two regression lines was found.
uET-1/min was higher in states of low urine osmolality. The urine flow
dependence of uET-1/min is not altered by water or salt diuresis.
Blunted renovascular response to subpressor angiotensin II after
chronic ACE-inhibition in normotensives at risk for hypertension. H.
Renovascular responsiveness to A2 (defined as the RBF decrement from
acute ACEI to A2 infusion) increased in FH— (before chronic ACE!:
301 75, after: 494 79 mI/mm) but failed to increase in FH+ (before
chronic ACET: 425 89, after: 366 74 mI/mm) (P < 0.01). After
pharmacological suppression of A2 generation, normotensives at risk for
hypertension show a blunted A2 responsivity of the renal vasculature. The
presented data are thus consistent with a hereditary, 'non-modulating,'
chronically stimulated renal A2 system in primary arterial hypertension.
Erythropoietin resistance. A. Colombi, S. Ruegger, and E. Gniter,
Kantonsspita!, Luzern, Switzerland. Patients (PAT) on renal replacement
therapy require different doses of recombinant human erythropoietin
(EPO) to maintain hematocrit (HK) levels in the range of 0.30 to 0.35.
EPO resistance has been suggested when high doses of EPO are needed.
Aim of our study: To analyze the EPO dose required in 29 PAT on chronic
hemodialysis (HD) and 26 PAT on continuous peritoneal dialysis (PD) to
keep HK in the above range and to investigate clinical signs and laboratory
markers for conditions known to cause EPO resistance. PAT with
polycystic kidney diseases were excluded. Results: EPO dose in HD-PAT
5.448 3.979 U/week, in PD PAT 1.885 2.044 U/w (P <0.001). Tn HD
PAT there is no significant correlation between EPO requirement and
serum ferritin levels, CRP, reticulocyte count, and intact PTH. EPO dose
also does not correlate with parameters of hemolysis (LDH). Further-
more, EPO dose was not affected by angiotensin converting enzyme
inhibitor, but aluminum-containing phosphate binders enhanced the
required EPO dose (P = 0.05). PAT with EPO doses <6.000 U/w required
increasing doses with increasing Kt/V; those with doses >6000 U/w in
1423
RBF FH+
FH+
after FH—
FH—
after
mI/mm before cACEI before cACEI
BL 926 46 932 59 904 68 1012 67
Acute ACEI 1219 85 1221 81 1102 83 1290 92
A2 infusion 794 29 855 46 801 52 796 43
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contrast required lower doses with increasing Kt/V. Extraordinarily high
EPO doses (14.188 8.626 U/w) were required in 16 HD PAT with failed
kidney grafts in situ, while 9 PAT who had nephrectomy after graft failure
required significantly less EPO (3.666 2.108 U/w, P < 0.001). PAT on
PD maintained IlK with the lowest dose of EPO even after graft failure.
After graft ncphrectomy one diabetic patient still needed high EPO dose
with a functioning pancreatic graft. Conclusions: (1) PAT on PD require
less EPO than PAT on HD to maintain HK of 0.30—0.35. (2) Up to a
cut-off level of 6.000 U/w we found a direct and above this level an inverse
correlation between the EPO dose and Kt/V. (3) Kidney grafts without
significant function increased EPO requirement in PAT returning to HD.
(4) The induction of EPO resistance is probably not specific for renal
grafts and may also result after transplantation of other organs. The
mediator causing this resistance is not yet known.
Risk factors for chronic renal allograft rejection. V.R. Broger Ribi, and
U. Binswangei; Nephrologie, Universitdtsspital, Zurich, Switzerland. Out of
266 recipients of renal allografts transplanted from 1988—1991, 34 were
diagnosed as suffering from chronic rejection by the observation of slowly
rising serum creatinine concentration, development of hypertension and
proteinuria. Occasionally, the diagnosis was directly proven by biopsy. For
comparison, 34 age- and sex-matched controls with normal transplant
function were selected. Data evaluated were as follows:
Patients Controls
HLA mismatches 4.6 1 4.5 1
Mean antibody titer %, 16/5 16/7
maximum/actual
Immediate function 29/34
Rejection <90 days, patients 20/34
Total 28
Severe 7
>90 days 9/34
Risk for primary CMV 6/34
CMV disease 4/34
Tmmuno.suppression
Prednisone withdrawal 6/34
Cyclosporine mg/kg/day 3.3 0.9
Serum trough level 130 42
Azathioprine mg/kg/day 0.8 0.4
At 3 years post-transplant
Cholesterol mmol/liter 5.7 1.3 5.6 1.2
Trigliccride mniol/litcr 2.2 2.3 1.8 1.2
Uric acid smol/liter 520 123 453 107
patients vs. controls, P < 0.05.
In conclusion, 2 or more severe early rejections, unsuccessful steroid
wthdrawa1, CMV infection and disease, and higher uric acid concentra-
tion are more frequently observed in chronic rejecting allograft recipients
than in controls.
Islet cell transplantation in IFNy receptor deficient mice. Are Th2 cells
upregulated? I Steige,; P. Nickerson, B. Ryffel, M. J-fermle, D. Roubaty, M.
Heim, and C. Thiel, University of Basel, Basel, Switzerland and University of
Manitoba, Manitoba, (anada. IFNy (ThI cytokine) is strongly associated
with rejection, down-regulates Th2 cells, is responsible for DTH and the
up-regulation of MI-IC class II. We therefore wanted to test the following
hypotheses: (a) signaling through the IFNy receptor (IFNyR) is relevant
for rejection; and (b) in the absence of IFNy signals Th2 cells would
dominate the immune response. We transplanted islets from DBA/2J
donors (J1-2') under the renal capsule of IFNYR knock-out (KO) mice
(H-25) and wild type (WT) controls. Recipient mice were rendered
diabetic one week prior to transplantation and graft function was deter-
mined by measuring blood glucose levels. All IFNyR KO mice rejected
their islet allograft without any delay as compared to WT controls.
Sequential histological examination on days 4, 6, 9 and 12 post-transplant
showed a cytodestructive mononuclear cell infiltrate of the islets in both
groups. To test whether rejection is mediated by T-cclls in IFNyR KO
mice, we treated the allograft recipients with anti-CD3 (25 jrg/day), which
is known to delay allograft rejection by neutralizing the T-cells. Under this
treatment none of the treated IFNyR KO mice rejected the allograft.
Intragraft cytokine gene transcripts from IFNyR KO mice and WT control
were analyzed by competitive template reverse transcriptase assisted
polymerase chain reaction on days 4, 6, 8 and 14 post-transplant. IL-2,
IL-4, IL-lO, IFNy, granzyme B and TCRcI3 gene transcripts were up-
regulated after transplantation and peak around day 8 in WT and IFNyR
KO mice. Interestingly, all gene transcripts, with the notable exception of
IL-4, are diminished at any given day in IFNyR KO mice compared to the
WT control. Regarding the Thl/Th2 paradigm it was striking that,
although IL-4 seems to he more highly expressed in this IFNy deficient
system, IL-b was markedly decreased. We conclude that rejection in an
IFNy deficient system occurs at the same tempo as in the WT control and
is T-cell mediated. Clearly, IFNY receptor signaling is not required for
allograft destruction. Although IFNyR signaling is absent and IL-4 is
expressed, IL-lO gene transcripts are markedly diminished. Thus, polar-
ized expression of TH2 cells was not evident. We hypothesize that
rejection in these mice is mediated by an IL-2 producing ThO like cell.
Tolerance induction by blocking costimulation: Is it important for the
T.cell to encounter the antigen? J. Steiger, P. Nickerson, W. Steurer, A.
Steele, M. Hermle, D. Roubaty, G. Thiel, and TB. Strom. University of Basel,
Switzerland, University of Manitoba, Manitoba, Canada, and Harvard
Medical School, Boston, Massachusetts, USA. Classical allograft rejection is
a T-cell mediated process. Two signals are required to activate T-cells.
Signal 1 is provided by the T-cell receptor and signal 2 (or costimulation)
by the interaction of CD28/CTLA4 on the T-cell to B7 on the antigen
presenting cell (APC). Blocking signal 2 during T-cell activation leads to
anergy in vitro and tolerance in viva. Therefore, blocking costimulation is
a very attractive target for immunomodulation. We constructed two
murine CTLA4 fusion proteins. In both forms we coupled the extramem-
branous part of CTLA4 to the Fcy2a part of the IgG2a. In one construct
we mutated the high affinity FcyRI receptor binding site and the C'lq
binding site. This results in 2 CTLA4/Fc fusion proteins: one with (L) and
the other without (NL) antibody dependent cellular cytotoxicity (ADCC)
and complement directed cytolysis (CDC) activity. The hypothesis is that
NL CTLA4/Fc binds to B7 but does not target APCs for ADCC or CDC.
The protein coats B7+ cells and thereby inhibits costimulation. Thus, we
hypothesized that NL CTLA4/Fc is more effective in achieving allograft
tolerance, then L CTLA4/Fc. We transplanted islets from DBA/2J or
Balb/c donors (H-2") under the renal capsule of B6AF1 mice (H-25).
Recipient mice were rendered diabetic one week prior to transplantation
and graft function was determined by measuring blood glucose levels. To
induce permanent engraftement we used 4 protocols: (1) NL; (2) L
CTLA4/Fc 100 .rg from day (—1)—14; (3) NL; or (4) L CTLA4/Fc 500 jg
on day 2 as a single dose. Using DBA'2J donors, the incidence of tolerance
is low (15—40%). There is no difference in allograft survival, if CTLA4/Fe
is given for 14 days or as a single dose, but interesting to note is that NL
CTLA4/Fc is more potent in inducing long-term engraftement when
compared to the L form (P < 0.02). Using Balh/c donors, permanent
engraftment is achieved in 85% (NL). Again the NL form results in a
higher number of long-term engraftement (P < 0.001). We conclude that
NL CTLA4/Fc is more potent in inducing permanent engraftment.
Targeting APC's for lysis might not he a good concept for tolerance
induction because T-cells must encounter the antigen. No difference is
seen when the protein is given on day 2 or for 14 days.
Urologic complications after two different techniques of ureteric anas-
tomosis for renal transplantation with the use of prophylactic ureteric
stents. M. Bianchetti, N. Frischmuth, T Gasser, P. Vogelbach, and G. Thiel,
Department of Innere Medizin und Chirurgie, Kanron,s.spital nod Univer,sitdt
Basel, Basel, Switzerland. Urologic complications after renal transplanta-
tion remain a major problem. Therefore, we compared two different types
of ureteric anastomosis techniques in renal transplant recipients. Each
technique was used over a period of one year. In June 1995 we switched
from the direct spatulated pull-through ureteric anastomic technique
(Modified Leadhetter-Politano, MLP) to an external ureteroneocystos-
tomy (UNC) technique. All of the 65 patients (39 male, 26 female) with
the MLP technique received a ureteric stent. These percutaneous ureterie
stents were usually removed 9—15 (mean 12.7) days post-transplant. All of
the 54 UNC patients (37 male, 17 female) received a double-J stent, which
was removed cystoscopically between 15 to 55 (mean 22.4) days after renal
29/34
13/34
14-
1/34
1/34
0/34'
20/34
3.2 0.9
136 47
0.8 0
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transplantation. The median age was 46.5 years in the MLP group and 46.4
years in UNC recipients. The MLP patients showed an overall urologic
complication rate of 27.7% (obstruction 10.7%, leakage 3.1%, clot reten-
tion 4.6%, vessel/ureteral angulation 3.1%, bleeding 2%, stent problems
3.1%, allograft pyelonephritis 0%) versus 18.5% in the UNC group
(obstruction 11.1%, leakage 1.8%, clot retention 1.8%, vessel/ureteral
angulation 1.8%, stent problems 0%, allograft pyelonephritis 1.8%). This
difference of overall complications between the two groups did not reach
statistical significance (chi-square test), but the odds ratio of 1.69 points to
a lower risk of complications in the UNC group. One patient in the MLP
group died due to ureter obstruction and leakage. No other allograft was
lost because of urological complications. Based on the slightly lower
complication rate we decided to continue the external UNC technique to
reconstruct the urinary tract in renal transplantation.
Follow-up of polycystic kidney disease patients in a chronic hemodial-
ysis center. D. Teta, A. Movaffaghi, F. Steinhauslin, G. Vogel, and J.P.
Wauters, Division de Néphrologie, Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland. Clinical manifestations of autosomal dominant
polycystic kidney disease (ADPKD) during chronic hemodialysis (HD)
seem to differ from those of patients with other causes of renal failure. In
this retrospective study, we have compared their morbidity, mortality and
vascular access obstructions with a matched control (C) group. From 1974
to 1994, 717 patients were enrolled in our HD program. Among 56
ADPKD patients, 48 (25 men, 23 women) could be analyzed and
compared to 48 (25 men, 23 women) of the C group. Mean age at start of
HD was 52 years (22—76) and 53 (25—76), respectively, while mean
follow-up (beginning of HD until death or transfer to another modality)
was 57 months (1—229) and 71 months (1—234). Eighty-eight % of the
ADPKD group and 92% of the C group suffered from arterial hyperten-
sion at some time during the follow-up period. Fifty episodes of gross
hematuria (important enough to prescribe rest) in 22 patients and 8 cyst
infections in 6 patients were observed in the ADPKD group while these
complications were absent in the C group. In contrast, the incidence of
acute pyelonephritis and lower urinary tract infections was not signifi-
cantly different (respectively 4 episodes of acute pyelonephritis in 4
patients of the ADPKD group vs. 15 in 4 of the C group and 26 episodes
of lower urinary tract infection in 15 patients vs. 22 in 13). Of 30 patients
with hepatic cysts, only 3 presented cyst hemorrhages, one cyst infection
and 2 cyst ruptures. Eight strokes in each group were identified of which
2 were hemorrhagic in the C group only. Ischemic heart disease was
recorded in 12 patients with ADPKD and 20 in the C group. A.V. fistula
obstructions were registered 79 times in 26 patients with ADPKD and 42
in 17 control cases (0.35 vs. 0.15 episode/year/patient). Twenty-two
patients of the ADPKD and 30 of the C group died. We conclude that in
this single center retrospective survey, ADPKD patients frequently
present specific complications during their HD period but cerebral and
cardiovascular morbidity is similar to controls; the incidence of vascular
access thrombosis is clearly higher, possibly related to higher hematocrit
and vascular reactivity.
Evaluating solute excretion in the neonate: Is the solute to creatinine
ratio in urine samples a good index? V. Matos and J.-P. Guignard,
Département de Pediatric, Centre ifospitalier Universitaire Vaudois, Lau-
sanne, Switzerland. Creatinine (Cr) excretion rate being relatively constant
in a given subject, the solute to Cr concentration ratio in single voided
urine samples yields a satisfactory standardization of solute excretion in
children and adults. To define whether this method was also valid in the
neonate (NN), we studied 48 healthy term NN (2 to 7 days old; median age
2 days) and 168 healthy children (age 1 month to 2 years). The urinary Cr
concentrations and osmolalities (osm) were determined from 2 morning
random urine samples collected 2—4 (neonates) and 7 days (children)
apart. In the NN, Cr concentration in the first urine sample was signifi-
cantly higher than in the second urine sample (P < 0.05); this difference
was not significant in the children's group. When the two groups were
compared, the Cr concentration was highly scattered and elevated in the
NN (P < 0.01). Even after correction for urine dilution (by using the Cr
to osm ratio), the levels of Cr remained elevated (see table):
Age
months
Ucr
range
p.mol/liter
Ucr
(median)
p.mol/liter
Ucr/osm
median
j.unol/liter
0.1 680—19300 7060 19.6
1—6 263—8550 1107 6.8
6—12 285—5807 1710 4.9
12—24 516—9970 2250 4.8
The high levels of urinary Cr and the important scatter of values observed
in the first days of life demonstrate that factors other than the lean body
mass and glomerular filtration rate (GFR) determine the creatinine
excretion rate. Clinical observations have shown that the NN inherits a
variable amount of creatinine from its mother, which will be cleared
during the first days of life. In addition, experimental evidence indicates
that the immature renal tubule is permeable to Cr, allowing back-diffusion
from the tubule to the blood. These two factors, as well as the rapid
maturation of the GFR in the first two weeks of life, probably determine
the high levels of urinary Cr and the important scatter in its excretion
observed in the NN. We conclude that the urinary creatinine concentra-
tion Cannot he used to standardize solute excretion in a single urine
sample in the neonate.
Different solute transport profile in pre- and postdilution hemodiafil-
tration with on-line production of bicarbonate infusate. D. Kiss, M. Loffel,
and J. Muser, Abteilung für Nephrologie, Med. Klinik, Kantonsspital Liestal,
Liestal, Switzerland. High-flux hemodiafiltration (HDF) presently offers
the most efficient extracorporal treatment modality in patients with
end-stage renal disease. On-line production of substitution fluid by cold
sterilization of dialysate permits virtually unlimited fluid volume exchange.
To find out the changes in solute transport along the molecular clearance
range during on-line pre- and postdilution HDF with different quantities
of infusate, we performed clearance (CL) studies in 14 chronic hemodi-
alysis patients. In predilution HDF the infusate amounted from 0—80
liters and in postdilution HDF from 0—20 liters. The reduction rate of urea
(MW = 0.06 kDa, of beta-2-microglobulin (MG/MW = 11 kDa) and
cystatin (CY/MW = 13 kDa) were determined. We used a Gambro
AK-100 ultra-pure dialysis machine for HD and on-line HDF and a
high-flux dialyzer (Polyfiux 21). The treatment time was 240 minutes, the
blood flow rate was set at 400 mI/mm and the dialysate flow rate was 700
mI/mm. The RR was calculated from the pre- and post-treatment value,
adjusted to the patients weight and intradialytic weight loss. Results are
expressed as mean (N = 13) and are given in %. Statistical analysis was
performed with the paired (-test.
HD Pre-HDF Post-HDF
Infusate liters 0 20 40 80 10 20
Urea-RR % 75 71 70 68 70 75
MG-RR % 58 61 67 74" 61 80"
CY-RR % 60 63 72" 71" 66 72"
a P < 0.05.
As a biochemically stable protease inhibitor, CY is proven to be superior
to beta-2-MG as a biochemical marker for determining the rates of middle
molecular removal. In postdilution IIDF there is no change in the
LM-RR, but there is a significant increase (+22%) of the MM-RR only
with 20 liters of infusate. In predilution HDF there is a decrease of the
LM-RR and a significant increase of the MM-RR. The maximal increase
(+ 16%) is achieved with 40 liters of infusate. The proven efficiency of
high-flux dialyzers with large surface area for dialysis means that the
benefits of HDF are comparatively slight.
Attenuation of anti-Thy!.! Nephritis by inhibition of matrix metallo-
proteinases. K Steinmann-Niggli and H.P. Marti, Abteilung für Nephrologie,
inseispital Bern, Bern, Switzerland. Anti-Thyl.1 nephritis represents a
well-characterized animal model of immune complex-mediated, mesangial
proliferative glomerulonephritis. After induction of anti-Thyl.1 nephritis
in rats, mesangiolysis is followed by an increase in proliferation of
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mesangial cells (MC) with augmented expression of matrix metallopro-
teinase-2 (MMP-2) and by an accumulation of extracellular matrix
(ECM); marked proteinuria occurs during the first days of the disease.
The aim of the present study was to determine the effect of the synthetic
MMP inhibitor, BB-1101, on the development of the nephritis. Four
groups of male Wistar rats were studied: healthy rats (N = 9), treated
healthy rats (N = 18), nephritic rats (N = 18), and treated nephritic rats(N = 18). The 63 animals were kept in metabolic cages. Anti-Thyl.1
nephritis was induced by intravenous injection of OX-7 IgG (1 mg/kg body
wt). The therapy consisted of intraperitoneal applications of BB-1 101 (30
mg/kg body wt/day), initiated 2 days prior to induction of nephritis.
Treatment of nephritic rats with BB-1 101 resulted in a significant decrease
of proteinuria: the median area under the curve of protein/creatinine
ratios versus time, considering 24 hour urine specimen during days 0—6,
was 0.97 g/mM, compared to 2.00 g/mM in the untreated nephritic group.
Non-nephritic rats displayed negligible proteinuria. Renal histology was
analyzed 11 days after induction of nephritis. Total cell count of glomer-
ular cross-sections (N = 63/group) in BB-1 101 exposed nephritic rats was
significantly less than in the untreated nephritic group (66 8 versus 85
12). Both groups of healthy animals displayed cell counts in the order of
55 10. The increased size of the glomeruli in nephritic rats was reduced
to almost normal by the MMP inhibitor. Accumulation of ECM in
nephritic rats was also ameliorated by BB-1101. Therefore, therapy of
nephritic rats with BB-1101 demonstrated beneficial effects in four
parameters, which are characteristic for the disease model. In conclusion,
MMP inhibition may represent a new approach to the treatment of
mesangial cell-mediated forms of glomerulonephritis.
TNFa and IL-lp enhance llp-hydroxysteroid dehydrogenase reduc-
tase activity in rat mesangial cells. G. Escher, B. S. Vishwanath, B.M. Frey,
and F.J. Frey, Abteilung für Nephrologie, Inselspital Bern, Bern, Switzerland.
Intracellular access of steroids to gluco- and mineralocorticoid receptors is
regulated by 11p-OHSDI and 11J3-OHSD2 which interconvert active
1113-OH- and inactive li-keto-steroids. The purpose of the present study
was to establish whether: (i) GMC express 11/3-OHSD; (ii) 11/3-OHSD, if
present, is relevant for the glucocorticoid effect in GMC; and (iii) GMC
stimulatory cytokines modulate 1113-OHSD. RT-PCR analysis revealed a
significant 11/3-OHSD1 and a negligible 11f3-OHSD2 expression. Differ-
ential measurements of the activities of 11p-OHSD isoenzymes in GMC
cultures and GMC extracts and analysis of Western blots demonstrated
the presence of 11p-OHSDI. In order to establish whether 11/3-OHSDI
modulates glucocorticoid effects in GMC, the inhibitory effect of cortico-
sterone on IL-113 stimulated group II phospholipase A2 (PLA2) was
analyzed. The potency of corticosterone to reduce transcription and
activity of PLA2 was increased by the addition of an inhibitor of
11 13-OHSDI. This effect of corticosterone was mediated by glucocorticoid
receptors as shown by experiments with RU 486. Stimulation of GMC with
IL-1p and TNFa, hut not IL-3, IL-6, PDGF or PMA, resulted in a
dose-dependent increase in expression of 1113-OHSD1, with a more than
5-fold increase in its reductase but not oxidase activity. This effect is
specific, since IL-l/3 and TNFa did not affect the reductase or oxidase
activity of the 1713-OH-steroid dehydrogenase. Conclusion: GMC express
significant amounts of 11$-OHSD1, which modulate the anti-inflamma-
tory effect of 1113-01-I-steroids. IL-1f3 and TNFa up-regulate specifically
the reductase activity of 1113-OHSD1 and by that mechanism counterbal-
ance their own stimulatory effect of cells in the presence of endogenous or
exogenous 1 113-OH-steroids.
Altered vasopressin (AVP) release and thirst sensitivity in male recur-
rent renal stone formers with low urine volumes (LVSF). B. Hess, 1..
Zipperle, R. Takkinen, K Farina, and Ph. Jaeger, Med. Universitdtspoliklinik,
Inseispital Bern, Bern, Switzerland. Low urine volume (LV) is a common
risk factor for recurrent nephrolithiasis. We studied 9 male LVSF (urine
volumes < 1200 mI/day on 2 or 3 occasions), aged 46.8 3.4 years and
compared them with 9 healthy male controls (C), aged 45.1 3.2 years.
After they fasted and abstained from tobacco, alcohol and caffeine
overnight, subjects were infused 5% saline at 0.06 mI/mm/kg for 120
minutes. At intervals of 15 minutes (including 15 and 75 mm after the
infusion was stopped), subjects rated their thirst on an uncalibrated visual
analog scale (10 cm), and blood was drawn for measuring plasma
osmolality (OSMO) and AVP (RIA, Nichols). Thresholds and sensitivities
for thirst and AVP release were obtained from the x-intercepts and slopes
of linear regression lines derived from correlations of thirst and AVP,
respectively, with OSMO. All values are means SE. Thresholds (293.7
2.1 vs. 294.1 2.7 mOsm/kg) for AVP release were equal in LVSF and C,
respectively, and AVP levels were similar in LVSF and C during saline
infusion. After cessation of saline infusion (between 15 and 75 mm), total
amount of AVP secreted over baseline (area under the curve) was higher
in LVSF than in C (248.3 33.5 vs. 79.3 25.0 pg/mI, P = 0.047).
Whereas thirst thresholds did not differ between LVSF and C (295.8 2.3
vs. 292.5 1.0 mOsm/kg), individual thirst sensitivities were lower in
LVSF (2.88 0.30 vs. 4.18 0.42 in C, P = 0.047). On respective plots
of pooled values of AVP and thirst ratings against OSMO, the slope of
increase in thirst with rising OSMO was significantly lower (P < 0.0001) in
LVSF (r = 0.51, slope 1.92, P = 0.0001) than in C (r = 0.79, slope 3.54,P = 0.0001). Whereas AVP levels were not correlated with rising OSMO
in C, a significant positive correlation was obtained in LVSF (r = 0.57,
slope 0.17, P = 0.0001). In conclusion, when challenged by a defined
osmotic stimulus (5% saline), LVSF exhibit reduced thirst sensitivity and
increasing AVP levels with rising OSMO, and elevated AVP secretion
persists after cessation of the osmotic stimulus. These abnormalities
appear to contribute to LV as a risk factor for recurrent renal stone
formation.
Routine biopsy of renal grafts: A high prevalence of cyclosporine-
associated arteriolopathy. G. Ashuntantang, R.E. Lemoine, C. Stoerrnann-
Chopard, J.-F. Bolle, P. Morel, and M. Leski, Division de Néphrologie du
Département de Medecine; Département de Pathologie, et Unite de Trans-
plantation du Département de Chiruigie, Hôpital Cantonal Universitaire de
Genève, Genève, Switzerland. Since November 1994, with the availability of
automatic biopsy needles, biopsy of renal grafts has become a routine
practice in our center. The aim is to identify asymptomatic and reversible
lesions at an early age. The histological diagnosis is done using the Banif
working classification of kidney transplant pathology. So far, a total of 50
biopsies have been carried out in 50 patients with stable renal function
with a mean age of 51 9.6 years. There were 33 males and 17 females.
The mean graft age was 5.96 2.7 years, with a range of 2 to 19 years.
Mean plasma creatinine levels were 124.9 19 .rmol/liters in the six
months preceding biopsy, and 127.7 21 jimol/liter at the time of biopsy.
The mean dose of cyclosporine A (CsA) used was 4.03 1.3 mg/kg/day;
3.15 0.95 mg/kg/day; 2.72 0.9 mg/kg/day and 2.61 mg/kg/day in the
first 3 months, the 6th month, the 12th month post transplantation, and
the 3 months preceeding the biopsy respectively. Whole blood CsA trough
levels were 331 61.7 rg/liter (N = 26), 257.7 77 j.tg/liter (N = 25); and
183.4 73 jig/liter (N = 14) in the first three months, the 6th month and
the 12th month post-transplantation, respectively. These were polyclonal
assays. In patients who had monoclonal assays, the CsA trough levels were
135.4 18 pg/liter (N = 21), 129.9 36 j.rg (N = 22), and 121.6 32
jig/liter (N = 34) in the first 3 months, the 6th month, and the 12th month,
respectively. The mean CsA trough levels using the monoclonal assay (the
only assay done in our center now), was 111.3 21 jig/liter in the 3 month
period preceding the biopsy in all 48 of the 50 patients on CsA therapy.
We found CsA arteriolopathy in 38 of the 50 grafts, 21 scored as grade I,
13 as grade II, and 4 as grade III. Among the 29 grafts of more than 5 years
of age, 23 had CsA-associated arteriolopathy, with 17 showing interstitial
fibrosis. Two of the 6 grafts without artermolopathy also showed interstitial
fibrosis. A striking finding was that of CsA-associated arteriolopathy and
striped fibrosis in a patient who had never received CsA. We found no
correlation between CsA dose, CsA trough levels, graft age and the
occurrence or degree of arteriolopathy. Furthermore, serum ereatinine
levels were not predictive of histologic lesions. In conclusion, CsA-
associated arteriolopathy is a frequent finding in CsA treated patients,
irrespective of dose and trough levels, especially given the fact that our
CsA doses are on the low side when compared to those reported in the
literature. There is no correlation between these lesions and contemporary
renal function even in grafts of more than 5 years of age. We therefore
question the prognostic significance of these lesions and the rationale for
lowering CsA doses when the latter are present. The specificity of these
lesions also becomes doubtful.
Renal hemodynamic effects of Bosentan, an endothelin antagonist, and
interaction with cyclosporine A: A placebo controlled double-blind study.
I. Binet, A. Wailnofer, R. Jones, and G. Thiel, Nephrologie Kantonsspital
Basel, and Hojfrnann-La Roche, Basel, Switzerland. Introduction: Endo-
thelin may play an important role in the cyclosporine A (C5A) induced
renal toxicity; therefore, we studied the effects of a non-selective ET-A
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and ET-B endothelin antagonist, bosentan (Bo), on the renal hemody-
namics, given alone and in combination with CsA. Methodology: A
double-blind randomized placebo-controlled crossover study was per-
formed in 7 healthy volunteers. Each received Bo 2 x 500 mg/day or
placebo, and a dose-adjusted regimen of Sandimmun Neoral® twice daily
to achieve CsA target trough levels of 200—250 ng/ml. A renal hemody-
namic study was performed on day 1 after a single dose of Bo or placebo
alone and on day 8, after 7 days of regular CsA intake with Bo or placebo.
The wash-out period was 14 days. Investigated parameters: blood pressure
(BP), inulin clearance (GFR), effective renal plasma flow by PAH
clearance (ERPF), sodium and lithium excretion fractions (FeNa, FeLi).
Results: A single dose of Bo lowered the diastolic BP (P < 0.05), but had
no effect on the renal hemodynamics. CsA + placebo over 7 days lowered
the ERPF with a nadir 4 hours after Sandimmun Neoral® intake. This fall
of ERPF, as well as the depth of the nadir, were significantly reduced by
CsA + Bo. However, CsA + Bo did not attenuate the fall in GFR and the
rise of BP observed with CsA + placebo.
GFR ERPF
Baseline 120 19 594 84
Bo single dose 114 20" 623 123
CsA + placebo (7 days) 103 20 490 93
CsA + Bo (7 days) 103 8 570 106h
Mean values SD.
not significant
= 0.01.
FeNa was significantly lower with CsA + Bo (1.6 0.6) as compared to
CsA + placebo (2.3 0.6) (P < 0.01). Since FeLi remained unchanged,
this sodium retention induced by Bo was not due to an effect on the
proximal tubule. Conclusions: Renal hemodynamics in healthy volunteers
are not affected by a single dose of Bo. Given 7 days in combination with
CsA, Bo does not prevent the reduction of GFR caused by CsA, but
reduces significantly the CsA-induced fall of ERPF and leads to sodium
retention. Assuming that CsA nephrotoxieity is mainly due to renal
vasoconstriction, then Bo has the potential to attenuate the renal toxicity
induced by CsA.
No evidence for hyperfiltration injury in "size mismatched" adult living
donor kidneys. HA. Bock, I. Binet, N. Frischmuth, P. Vogelbach, Th.
Gasser, and G. Thiel, Division of Nephrology and Organ Transplantation,
Kantonsspital Basel, Switzerland. Since hyperfiltration injury may contrib-
ute to chronic renal allograft failure, it has been suggested that relatively
small kidneys should not be transplanted into relatively big recipients. To
evaluate this hypothesis in the context of living donor kidney transplan-
tation, we studied the 104 adult living donor kidney recipients trans-
planted between 12/88 and 12/94 at our institution. Donors underwent
renal function study (inulin clearance and microalbuminuria) before, 1
week after, and 1 year after nephrectomy/transplantation; recipients were
studied at 1 month and 1 year. Eleven donor-recipient pairs were excluded
from analysis; causes included graft loss within the first year (2), ongoing
rejection at the time of the I-year study (1) and incomplete clearance data
(8). Mean donor GFR before nephrectomy (± SD) was 96 20 mI/mini
1.73m2 body surface area (BSA). A "size mismatch" (MM) was assumed
to exist if 50% of the donor GFR, divided by the recipient's BSA, was
below the 99% confidence limit for 2-kidney GFR (<45 ml/minil.73 m2).
According to this definition, there were 34 "size MM" and 59 "size
matched" kidneys:
Donor Recipient
GFR pre-NX hyperfiltration GFR at GFR at
mi/mm GFR/preNx/2 1 month 1 year
"Size MM" 79 2' 121 5% 47 2C 46 35
NoMM 110±2 100±3% 55±2 56±2
Despite lower GFR and more hyperfiltration, GFR in "MM" kidneys
remained stable, and microalbuminuria at one year (111 40 vs. 127 48
mg124 hr) as well as the mean number of antihypertensive drugs (1.2 vs.
1.3) did not differ between the two groups. Post-Nx hyperfiltration was
even more pronounced in the donors (129 2%), yet caused neither
microalbuminuria nor loss of renal function. In conclusion, at one year
after transplantation, there is no evidence for "hyperfiltration injury" in
size-mismatched adult living donor kidneys. The degree of kidney size
mismatch usually found among adults does not require size matching.
Long-term follow-up of hemodialyzed patients with the urea monitor:
Improvement of dialysis adequacy but not nutritional parameters. G.
Vogel, D. Teta, and I P. Wauters, Division de Néphrologie, Centre Hospitalier
Universitaire Vaudois (CHUV), Lausanne, Switzerland. Total dose of
dialysis expressed as Kt/V and protein catabolic rate (PCR) is presently
considered to be major determinants of morbidity and mortality in
chronically hemodialyzed patients: a total Kt/V 1.2 and normalized PCR
(nPCR)  1.0 are now widely recommended. The urea monitor allows
measurement of urea kinetics on-line on the dialysate side and thus
provides an easy tool at the bedside. From October 1994 till August 1996,
a trimestrial measurement of Kt/V and PCR was done in all our center
patients (N = 111, 58 men and 53 women). Based on pre- and post-dialysis
urea levels, all patients appeared to receive an adequate dialysis. After the
first measurement, the patients were stratified into 4 groups according to
their total Kt/V ( or <1.2) and nPCR ( or <1.0). In patients of group
A (N = 23) with Kt/V z1.2 and nPCR l.0, no modifications in dialysis
schedule or diet were performed. In group B (N = 12) with Kt/V <1.2 and
nPCR 1 .0, dialysis therapy was increased by changing successively blood
flow and dialyzer's surface. Patients in group C (N = 48) with Kt/V  1.2
and nPCR <1.0 were prescribed a liberalized regimen and additional oral
nutritional support. In patients of group D (N = 28) with Kt/V <1.2 and
nPCR <1.0, both intensified dialysis and nutritional supply were intro-
duced. After 18 months of follow-up, Kt1V in group A diminished due to
decline in residual renal function over time but remained within the
prescribed range. For patients in groups B and D with low Kt/V,
modification of the dialysis session was followed by an increased Kt/V. In
contrast, modifications of nPCR by dietary manipulations were possible
during a six month period only and patient's compliance declined after-
wards. Sixteen patients died during the follow-up: 7 were in group D and
4 in group C, while only 2 were in group A. We conclude that: (1) the
bedside use of the urea monitor allows tailoring dialysis and nutritional
therapy in a repeatable and individualized way; (2) dialysis modifications,
even minor, are generally effective; (3) a more aggressive and persuasive
approach is needed in order to improve nutritional parameters.
Death with functioning graft—An underrated cause of "chronic renal
aflograft failure." St. Schaub, HA. Bock, and G. Thiel, Abteilung Neph-
rologie, Kantonsspital Basel, Basel, Switzerland. Standard survival curves
frequently form the basis for speculating about the roles of chronic
rejection, drug nephrotoxieity, and other factors considered harmful to
renal allografts. These standard procedures, however, fail to consider
death with intact graft. We wondered whether considering death with
intact graft a "censored" endpoint (similar to the patient being lost to
follow-up) would affect the interpretation of the post-transplant course in
some typical diagnostic and age groups. We used a cohort of 491 cadaveric
renal grafts transplanted at our center since 1981 with CsA-based initial
immunosuppression. Graft losses were considered censored, if estimated
creatinine clearance at the time of death was l0 mi/mm. Overall, 108 of
231 graft losses (47%) were due to death with a functioning graft. While
standard survival calculations showed extremely poor 10-year graft sur-
vival in patients with diabetic and analgesic nephropathy (table), the
"death-censored" approach demonstrated that graft survivalperse in these
groups was essentially similar to controls.
Primary renal disease
10-year graft Diabetic Analgesic other
survival N = 43 N = 94
-
N = 354
"Standard" 29% 33%" 50%
Death-censored 54% 68% 70%
"p < 0.05 vs. "other" renal diseases
Mean SCM.
'P < 0.005, 'P < 0.01, "P < 0.05 MM vs. no MM.
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In contrast, the "death-censored" method uncovered that younger pa-
tients incur a much higher risk of losing their graft than older ones
("death-censored" 10 year rates were 51, 68 and 72% for patients <35
years, 35—60 years and > 60 years, respectively; P < 0.005), which was not
at all evident from standard calculations (47, 45 and 32% at 10 years; P =
0.30). In conclusion, the assessment of the net immunosuppressive effects
of different drug regimens or comparisons among transplant centers with
different acceptance policies should be based on death-censored survival.
Cyclosporine A pharmacokinetics—Comparison between the standard
and the new microemulsion formula using a population-based approach.
F. Schaedeli, F.J. Frey, H.P. Marti, and D.E. Uehlinger, Departement Innere
Medizin, Abteilung für Nephrologie, Universitdt Bern, Bern, Switzerland.
Steady-state pharmacokinetics of once daily administered cyclosporine A
(CsA) were investigated in 60 stable renal transplant recipients before and
after conversion from the standard formula (S) to the microemulsion
formula Neoral® (N). The aim of the study was to investigate the
correlation of 12 hour and 24 hour trough levels with the 24 hour area
under the curve [AUC(0—24 hr)1 in S and N for an adequate dose
adjustment after the conversion, and to develop a reliable method for
individual AUC prediction for clinical routine monitoring of N. For each
of the two formulae, 7 samples per patient were collected from 50 patients
(group A) at random time points within two weeks, and 10 blood samples
per patient were collected from 10 patients (group B) at fixed time points
within 24 hours. A two-compartment population kinetic model assuming
time lagged first order oral absorption was fitted to the data of group A,
using nonlinear mixed effects modelling (NONMEM), whereas the phar-
macokinetic parameters of group B were estimated by classic model
independent methods. The data of group B were used to evaluate the
predictive power of the population kinetic model. Results are expressed as
mean values (coefficient of variation). Mean S doses of 245 (38%) mg
resulted in whole blood CsA levels of 214 (32%) ng/ml after 12 hours and
of 108 (21%) ng/ml after 24 hours, whereas with mean N doses of 206
(30%) mg, CsA levels were 212(28%) ng/ml and 132(25%) ng/ml after 12
and 24 hours, respectively, as measured by specific fluorescence polariza-
tion immunoassay (TDx). Assuming no differences in the elimination
between the two oral formulae, the estimated bioavailability of N was 25%
higher as compared with S. A strong correlation between 12 hour levels
and AUC was observed for N, but not for S; the correlation between 24
hour trough levels and AUC was weak for both formulae. The population
model of group A predicted individual AUCs of patients from group B
with a median deviation of 15% (4% to 52%) from the measured AUCs
for N, and 24% (7% to 140%) for S. Switching the oral CsA application
from S to N resulted in 60% higher CsA peak levels leading to adverse
events that necessitated a change from a once daily to a twice daily dose
regimen in some patients.
Long-term recovery of cortical and trabecular bone mass after renal
transplantation is modulated by daily dose of cyclosporine A and resolv-
ing hyperparathyroidism. F.F. Horber, K. Lippuner, and Ph. Jaeger, Klinik
Schloss Mammern and Policlinic of Medicine, University of Berne, Beme,
Switzerland. Renal transplant patients (RTP) have high trabecular bone
fracture rates, probably due to glucocorticoid-induced osteopenia.
Whether resolution of secondary hyperparathyroidism and/or continuous
reduction of the daily dose of prednisone (DDP, mg/kg/day) as well as
dose of cyclosporine A (CsA) applied modulate the known differential
effects on trahecular and cortical bone following renal transplantation
(RT) in the long run remains unknown. Therefore, 24 RTP (12 females, 12
males) were investigated at 10 1158 5, 255 5, 349 5, and 524
9 days after RT using DXA technique (Hologic QDR 1000/W). Trabec-
ular compartment (TC) comprised spine, ribs, and pelvis, whereas cortical
compartment (CC) included arms and legs. During the firstS months after
RT, bone area (BA), bone mineral content (BMC) and density (BMD) of
TC decreased to 96.9 0.7%, 91.9 1%, and 94.8 0.6%, respectively(P <0.001 vs. baseline). Thereafter BA, BMC, and BMD of TC increased
continuously reaching significantly higher values when compared with 5
months (98.5 0.8% for BA, 97.9 1.3% for BMC, and 99.5 0.8% for
BMD, respectively) after 1 year. When compared with controls, BA, BMC
and BMD of TC and its subregions where still decreased in females but
not in male patients 1.5 years after RT. In contrast to TC only BA and
BMC, hut not BMD, of CC increased continuously after RT reaching
104.2 1.3% and 103.6 1.7% of baseline for BA and BMC, respectively,
after completion of study, whereas BMD of CC remained unchanged
(99.1 0.9% of baseline after 1.5 years). BA and BMC of CC were still
significantly lower than those observed in controls in females, but not in
male patients at the end of the study. Lumbar and upper femoral BMD
demonstrated similar changes over time as observed for TC. Logarithmic
serum concentrations of intact PTH at time of RT were correlated with
relative changes, occurring during the 1.5 years of observation in BA,
BMC and BMD (r = 0.42, P < 0.04) of CC, but not of TC. No correlation
between cumulative dose of prednisone or DDP and change in bone
measurements of all densitometric parameters analyzed were detected
between all time points (r < 0.25) of CC and CT. In contrast, the decrease
in DDP correlated positively with recovery of CC-BA and BMC (r = 0.45,
P < 0.02), but not BMD. Cumulative dose of CsA per kg body weight
during the first 5 months did not influence the decrease observed in the
TC (r < 0.3), whereas in the remainder of study, BMD of TC (but not BA
and BMC) correlated positively with cumulative dose of CsA (r = 0.44,
P < 0.05). Moreover, BA and BMC, but not BMD of CC increased (r <
0.5,P < 0.01) with increasing dose of CsA over the 524 days of study. The
present data collectively suggest that not only cortical bone recovers
following RT (modulated by PTH at time of RT, change in DDP and
cumulative dose of C5A), but also TC (modulated by cumulative dose of
CsA) despite ongoing immunosuppressive therapy with prednisone, reach-
ing pretransplantation values in males but not in female patients.
Continuous monitoring of blood volume change steering ultrafiltration
during hemodialysis: Patient results. A. Knoflach, H.D. Polaschegg, and U.
Binswanger, Nephrologie, Universitatsspital, Zurich, Switzerland. Seven
chronic stable hemodialysis patients were studied during several treat-
ments using continuous ultrafiltration in order to reach dry weight.
Continuous hematocrit recording (Crit line) identified delta hematocrit
increase (delta blood volume decrease) associated with hypotension. This
delta crash crit level minus 1% was set as the limit for ultrafiltration being
automatically switched on and off by means of an adapter connected to a
Fresenius 2008 monitor during the "experimental" treatment with ultra-
filtration rate at 1200 mI/hr. Results were as follows:
Patient
Men/women
bodyweight
UF
Goal
(ml)
Observed
Dialysis
Time,
mm
UF goal reached
Time,
mm
I 58.5/rn 2050 2050 180 105
2 63.5/w 1900 1910 180 90
3 82.5/w 2250 2260 180 165
4 47/rn 1150 1190 180 65
5 84.5/rn 3400 3386 205 205
6 45.5/w 1350 1370 150 90
7 38.5/w 2650 2658 180 170
Mean 2107.14 2117.71 179.29 127.14
SD 766.17 751.46 15.92 52.35
Conclusion: Hematocrit guided ultrafiltration control permits high initial
volume decrease followed by "isovolernic" dialysis. The procedure does
not prolong treatment time. Patient tolerance was excellent without
hypotension during treatment.
Is heparin therapy necessary in CAPD peritonitis? C. Nadig, U
Binswanger, and A. von Felten, Nephrologie, Department of Internal Medi-
cine, Universitätsspital, Zurich, Switzerland. Heparin therapy in CAPD
peritonitis seems well-established; it is costly due to the necessity of
hospitalization. There are no clinical studies which show benefits of such
treatment. The aim of this study was to investigate if heparin therapy in
CAPD peritonitis is necessary. One hundred ninety-four samples of
peritoneal dialysates were collected from 17 patients over a period of 24
months. Samples were subdivided into a group without peritonitis (<100
leukocytes/jil), a group with mild peritonitis (100—499 leukocytes/pi) and
one with severe peritonitis (500 leukocytes/pi). The number of leuko-
cytes per j.d dialysate and total protein concentrations were determined.
Further, dialysates were analyzed by measuring thrombin-antithrombin III
(TAT) complexes (indicator of thrombin formation), D-dimers (indicator
of fibrinolysis) and PAl-I (plasminogen activator inhibitor 1). The protein
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concentration rose progressively from no peritonitis to mild and severe
inflammation. In parallel, TAT complexes and D-dimers increased and
correlated strongly in 179 cases (r = 0.76; 62 samples showing peritonitis,
117 samples with no peritonitis). However, in the remaining 15 samples of
3 patients, high PAl-I levels (>40 ng/ml) and low D-dimers were found.
Eleven of the 15 samples showed peritonitis, 4 did not. In the 11 samples
with peritonitis, high levels of TAT complexes were measured while
D-dimers were found to be very low, pointing to a blocked fibrinolysis. The
PAl-i levels were not related to leukocytes or protein concentrations in
the dialysates. According to our findings, the general application of
heparin in CAPD peritonitis is not necessary. Rare eases can he found
with an imbalance of coagulation and fibrinolysis due to high PAl-i levels
(15 of 194 dialysate samples, II of the 15 samples showing peritonitis).
These cases—which need heparinization—can be identified by measuring
low D-dimers in CAPD dialysate at times of peritonitis.
Effect of chronic metabolic acidosis on the growth hormonc/IGF-1
endocrine axis: New cause of growth hormone insensitivity in humans. M.
Brungger, H.N. Hulter, and R. Krapf Kantonsspital, St. Galien, Switzerland.
The effects of metabolic acidosis on growth hormone and 1GF-1 are poorly
understood. We investigated the effects of chronic metabolic acidosis
(induced by administration of NH4CI, 4.2 mmol/kg body wt per day) on the
growth hormone/IGF-1 endocrine axis in 6 normal male volunteers during
metabolic balance conditions. NH4CI administration resulted in hyper-
chloremic metabolic acidosis with plasma bicarbonate decreasing from
25 0.4 to 15.5 0.9 mmol/liter (P < 0.001). Metabolic aeidosis
significantly decreased serum IGF-1 concentration from 45 6 to 33 6
nmol/liter (P = 0.002), while serum TGF binding protein 3 concentration
was not affected significantly. The growth hormone response to growth
hormone releasing factor administration (1 pg per kg body wt, intravenous
bolus) was enhanced significantly during acidosis. The IGF-i response to
growth hormone administration (0.1 U kg body wt subcutaneously, every
12 hours for 48 hours) was blunted significantly during acidosis. Apparent
endogenous serum half-life and metabolic clearance rates of growth
hormone were not altered significantly by acidosis. Metabolic acidosis in
humans results in a significant decrease in serum IGF-l concentration
without a demonstrable effect on IGF binding protein 3 and is related to
a resistance to the hepatocellular action of growth hormone. The primary
defect in the growth hormone/IGF-1 axis occurs via an impaired JGF-i
response to circulating growth hormone with consequent diminution of
normal negative feedback inhibition of IGF-1 on growth hormone as
evidenced by the exaggerated growth hormone response to growth hor-
mone releasing factor administration.
Impact of dietary advice on urinary supersaturation in male recurrent
idiopathic calcium renal stone formers (RCSF). B. Hess, H. Mauron, R.
Miche4 I). Ackermann, and Ph. Jaeger, Medizinische Poiiklinik und *Urolo
gische Klinik der UniversitOt Bern, Bern, Switzerland. Low urine volume and
high meat protein intake are recognized epidemiologieal risk factors of
calcium ocphrolithiasis. By means of EQUIL 2, we calculated relative
supersaturations of calcium oxalate (RSa0a) of 24 hr urincs of 68 healthy
male controls (C, 1 urine collection) and 40 male RCSF before (2 or 3
urines) and after (1 urine) dietary advice (DA) had been provided as the
only treatment. The main goals of DA were: (1) to keep urine volume (V)
above 2000 mI/day; and (2) to reduce meat protein intake to 5 servings!
week. Except for UNa x V which fell from 234 12 to 203 ii mmol/day
(P — 0.003), no significant changes were noted in urines of RCSF after
DA, and RScaux was unchanged. However, when dividing RCSF into
hypercaleiurics (HCSF, U. X V > 9.00 mmol/day, N = 14) and
normocalciurics (NCSF, N = 26), reasons for the apparently lacking
effects of DA became more evident (24 hr urine excretions, means sli):
DA
1-ICSF
V ml Uvrea X V mmol RSa0x
Before 2366 181 505 23 8.90 1.01
After 2165 222 421 29k' 8.91 1.01
DA
NCSF
V ml U, >( V mmoi RS0
Before 1793 10 426 32 5.65 0.56
After 2061 123 463 30 6.20 0.60
a P < 0.05 vs. before DA
Since protein consumption (Urjrea >< V) was elevated in HCSF, DA mainly
aimed at reducing protein intake which indeed was reduced; however, V
also tended to fall. In NCSF, DA primarily focused on V which actually
rose, as did—unintentionally—U00. >< V, U0, X V, >< V and thus
RSa0. When pooling all 24 hr urines from HCSF and NCSF before and
after DA (N = 103), the single parameter which best predicted RSa0x
was urinary oxalate concentration (r = 0.816, P = 0.0001). In conclusion,
DA may only be successful in reducing RSaox if both V as well as meat
protein intake are addressed in all RCSF. In addition, we demonstrate
that urinary [Oxi is the most simple clinical index of RSa0,.
Reduced proteinuria on combined verapamil SR/quinapril instead of
nifedipine CRlquinapril in a patient with diabetic nephropathy. D. von
Daeniken, D. ROsier, R. Cacciatore, R. Sieber, and B. Hess, Medizinische
Klinik, Zieglerspital, Bern, Switzerland. Short-acting nifedipine (N), al-
though it efficiently lowers blood pressure (BP), may increase proteinuria(U,0) in patients with diabetic nephropathy (DN); no data exist on the
effects of long-acting forms of N on Upr,,. Other calcium channel blockers
(CCB), such as the non-dihydropyridines, are able to reduce Ujrot in
patients with DN, and combined verapamil/ACE inhibitor treatment
produces greater reduction in Upr,t and better preservation of renal
function than either compound alone. A 66-year-old woman with a 19-year
history of diabetes mellitus (insulin-dependent) and hypertension with
overt nephropathy, polyneuropathy and retinopathy was admitted for
treatment of a foot ulcer. Main findings were as follows: 164 cm, 76 kg,
massive edema, BP 170/80 mm Hg, heart rate 80/mm, glucose 6.9
mmol/liter, HbAlc 8.0%, creatinine 219 smol/liter, albumin 17 g/liter,
CRP 61 mg/liter, Lc 10.1 x 109/liter. While still on the previously
established combination therapy with nifedipine CR 60 mg/quinapril 2 x
20 mg/day and with BP values of 140—180/60--80 mm Hg, Cr was 20.9
ml/min./1.73 m2 and UprOt 9.0 g/24 hr. Whereas all other treatment
modalities were unchanged, antihypertensives were switched to verapamil
SR 120 mg/quinapril 2 x 20 mg/day. After I month, BP remained at
140—160/70—80mm 1-Ig, Ccr was 16.1 ml/min./1.73 m2, and Upr,, returned
to 5.3 g/24 hr. After 2 months, with stable BP values and serum albumin
of 24 g/l, Cr and Uprot were 16.7 ml/min./1.73 m2 and 3.6 g/24 hr,
respectively. The effect was sustained after 7 months, when respective
values were 15.0 ml/min/l.73 m2 and 1.6 g/day. In conclusion, it appears
that the antiproteinuric efficacy of combined CCB/ACE inhibitor treat-
ment in DN may he affected by the type of CCB, and we suggest that
long-acting nifedipine, despite its BP lowering activity, may have contrib-
uted to the massive proteinuria observed in the present case.
Histological features of cellular renal allograft rejection correlated with
clinical parameters: An analysis of 111 cases. V. Nickeleit, E.G. Vamvakas,
M. Pascua4 J. Poletti, and R.B. Goivin, Massachusetts General Hospital,
Boston, Massachusetts, USA; St. Vincent Med. Center, Los Angeles, Caiifrr-
nia, USA; and University of Basel, Basel, Switzerland. Background: The
diagnosis of acute cellular rejection (ACR) in renal allograft biopsies (bxs)
is based on the presence of a mononuclear cell infiltrate, tubulitis, and
endothelialitis (= eodarteritis), which is regarded as typical for ACR.
however, little is known about the prognostic and therapeutic significance
of these histologic features. Design: One hundred eleven renal allograft
bxs with ACR were analyzed (excluding chronic rejection). The study was
limited to early hxs (41 38 days post transplantation; 80 initial hxs)
performed for deterioration of graft function. Sixteen histological criteria
were scored and correlated with clinical parameters lone year graft
survival, 6 month and 12 month serum ereatinine levels (Cr), and response
to steroid or antibody therapyj. Results: Patients without endothelialitis
showed a better response to bolus steroid treatment (serum ereatioine
110% of baseline) than those with endothelialitis (total N = 75;P = 0.03).
Endothelialitis did not correlate with antibody treatment (N 61; P =
0.78). Patients with fibrinoid vascular necrosis did not respond to either
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steroids or antibodies. Larger numbers (>4) of sampled arteries showed
an improved accuracy in predicting steroid response. Fibrinoid vascular
necrosis (N = 4; 3.6%) showed a statistically significant poor one year
graft survival (P = 0.007). Eridothelialitis (regardless of the number of
affected vessels or the degree of intimal inflammation, N = 60; 54%),
sticking of mononuclear cells to the endothelium, the extent of the
interstial infiltrate (with or without eosinophils) or tubulitis did not reveal
any statistically significant correlation with elevated 6 month or 1 year
serum creatinine levels or one year graft survival. Conclusion: In ACR
fibrinoid vascular necrosis has an adverse effect on one year outcome.
Endothelialitis correlates with steroid resistance but is not associated with
response to antibody treatment. Endothelialitis does not predict poor
outcome at one year.
Islet cell transplantation in IFNy receptor deficient mice. Are Th2 cells
up-regulated? J. Steiger, P. Nickerson, B. Ryffl, M. Hermie, D. Roubaty, M
Heim, and G. Thiel, University of Basel, Basel, Switzerland and University of
Manitoba, Manitoba, Canada. IFNy (Thl cytokine) is strongly associated
with rejection, down-regulates Th2 cells, is responsible for DTH and the
up-regulation of MHC class It. We therefore wanted to test the following
hypotheses: (a) signaling through the IFNy receptor (IFNyR) is relevant
for rejection; and (b) in the absence of IFN-y signals Th2 cells would
dominate the immune response. We transplanted islets from DBAJ2J
donors (H-2") under the renal capsule of IFNyR knock out (KO) mice
(H-2") and wild type (WT) controls. Recipient mice were rendered
diabetic one week prior to transplantation and graft function was deter-
mined by measuring blood glucose levels. All IFNyR KO mice rejected
their islet allograft without any delay as compared to WT controls.
Sequential histological examination on days 4, 6, 9 and 12 post-transplant
showed a cytodestructive mononuclear cell infiltrate of the islets in both
groups. To test weather rejection is mediated by T cells in IFNyR KO
mice, we treated the allograft recipients with anti-CD3 (25 j.tg/day), which
is known to delay allograft rejection by neutralizing the T cells. Under this
treatment none of the treated IFNYR KO mice rejected the allograft.
Intragraft cytokine gene transcripts from IFN'yR KO mice and WT control
were analyzed by competitive template reverse transcriptase assisted
polymerase chain reaction on days 4, 6, 8 and 14 post-transplant. IL-2,
IL-4, IL-lO, IFNY, granzyme B and TCRc13 gene transcripts were up-
regulated after transplantation and peaked around day 8 in WT and
IFNYR KO mice. Interestingly, all gene transcripts, with the notable
exception of IL-4, are diminished at any given day in IFNyR KO mice
compared to the WT control. Regarding the Thl/Th2 paradigm, it was
striking that, although IL-4 seems to be more expressed in this IFNy
deficient system, IL-lO was decreased most markedly. We conclude that
rejection in a IFNy deficient system occurs in the same tempo as in the
WT control and is mediated by T cells. Clearly, IFNY receptor signaling is
not required for allograft destruction. Although IFNyR signaling is absent
and IL-4 is expressed, IL-lO gene transcripts are most markedly dimin-
ished. Therefore, polarized expression of TH2 cells was not evident. We
hypothesize that rejection in these mice is mediated by an IL-2 producing
ThO like cell.
Bradykinin B2 receptor blockade interferes with renal functional
development. P. Toth-Heyn, M. Thonney, and J.-P. Guignard, Service de
Pediatric, Unite de Néphrologie, CHUI/, Lausanne, Switzerland. The renal
kallikrein-kinin system (KKS) has been claimed to regulate morphological
and functional renal maturation besides regulating neonatal glomerular
hemodynamics. The present study was performed to investigate the
influence of bradykinin (BK), acting via 82 receptors, on the development
of renal function. Newborn rabbits were treated with the B2 receptor
blocker Hoe 140 s.c. from the age of 4—5 days until the age of 8—9 days
(N = 8). Hoe 140 was administered twice daily in a dose of 300 zgIkg. In
preliminary experiments we demonstrated that this dose of Hoe 140
effectively inhibits B2 receptors for at least 6 hours in our experimental
model. A control group received the same volume (0.1 ml/100 g) of 0.9%
NaCI s.c. twice daily (N = 8). Clearance studies were performed in
anesthetized newborn rabbits at the age of 8—9 days. Renal plasma flow
and glomerular filtration rate (GFR) were determined by PAH and inulin
clearances, respectively. Besides measuring baseline renal hemodynamics,
systemic hypoxemia-induced changes were also determined in both
groups. Chronic B2 receptor inhibition did not cause any difference in the
kidney weights of experimental groups. Baseline blood pressure was very
similar in the two groups. Renal blood flow (RBF) was higher in Hoe
140-treated newborn rabbits, but there was no difference in GFR. Control
rabbits had higher filtration fraction (FF). No differences were observed in
urine flow rate and sodium excretion. Systemic hypoxemia resulted in
similar renal vasoconstriction in both groups. In control rabbits a decrease
in GFR was observed, while in the Hoe 140 group GFR did not change,
but FF increased significantly. The similar kidney weights in both groups
indicate that BK does not promote neonatal renal growth. The observed
difference in baseline renal hemodynamics confirms the role of BK in the
functional renal maturation. Chronic B2 receptor inhibition may lead to
increased RBF either by blocking the antiproliferative effect of BK or by
disturbing the balance of vasoconstricting and vasodilating forces in the
developing kidney. The predominant role of the vasodilating property of
BK is supported by the modified vasoresponse to hypoxemia in Hoe 140
pretreated rabbits. In conclusion, intact renal KKS is necessary for the
normal functional development of the neonatal kidney.
Is Neoral more nephrotoxic than Sandimmun? A prospective study. N.
Frischmuth, P. Vogelbach, HA. Bock, and G. Thiel, Abteilung für Innere
Medizin und Chirurgie, Kantonsspital Basel, Basel, Switzerland. To evaluate
whether Sandimmun (Neoral) is more nephrotoxic than "classic" Sand-
immun, we prospectively studied living donor kidney recipients (excluding
HLA identical siblings) who received either Sandimmun (12/88—10/94,
N = 92) or Neoral (1/95—10/96, N = 37) from the time of transplantation
throughout the first year. Renal function (C-inulin, C-PAH, 132 micro-
globulin clearance (C-/32m) and albumin excretion rate (AER), cyclospo-
rine trough levels (CsA TL) and daily dose (C5AJD) were measured at 3
weeks and 1 year after transplantation. The two groups did not differ with
respect to age, gender distribution, initial immunosuppressive regimen
and concomitant medication (ACE inhibitors and Ca antagonists). The
results are shown below.
N
CsA
CsA/D TL
mg/kg p.g/liter
C-inulin
mI/mm
C-PAH
mi/mm
San 3 weeks
Neo 3 weeks
San 1 year
Neo 1 year
96
37
84
12
7.2 0.2 249 9
6.8 0.4 295 21
5.3 1.0 156 8"
4.9 0.5 194 20"
52 2
50 354 2
53 6
319 10
318 18
254 12"
272 35
C-132m mi/mm AER mg124 hr
San 3 weeks
Neo 3 weeks
San 1 year
Neo 1_year
3.7 0.9
2.2 0.6
2.1 0.4
1.2 0.7
120 16
130 23
140 60
70 28
Mean values (±sEM) for both groups. a P < 0.05; "P < 0.001
1 year vs. 3 week values.
There was no difference between the two groups concerning CsA!D and
CsA TL at 3 weeks or 1 year but there was a trend to higher CsA trough
levels despite lower daily dose in the Neoral group. We found a significant
decrease of C-PAH after one year in the Sandimmun but not in the Neoral
group. C-132m as a marker of tubular toxicity and AER as a marker of
glomerular toxicity tended to be lower in the Neoral group. Conclusion:
The present data with a follow-up of one year provide no evidence of
increased nephrotoxicity of Neoral compared to Sandimmun despite a
higher bioavailability.
The effects of dimethyl sulfoxide used in solvent concentrations on the
newborn rabbit kidney function. MN. Riftema, D. Mosig, and i-P.
Guignard, Département de Pediatric, CHUV, Lausanne, Switzerland.
Dimethyl sulfoxide (DMSO) is a solvent, used frequently to dis-
solve cyclosporine, nifedipine and 8-cyclopentyl-l ,3-dipropylxanthine(DPCPX). Clinically it has been used for the treatment of interstitial
cystitis (RIMSO 100®) and for the treatment of scleroderma (Kemsol®).
Abstracts
Intravenous administration of DMSO in adult rats with doses varying
between 7.4—770 jig/kg hr has been shown to be without effect on the
kidney function. The purpose of the study was to evaluate the effects of
DMSO on the immature kidney. The experimental protocol included a 90
minute equilibration period, a 60 minute control period and a 90 minute
lasting experimental (treatment) period. Two groups of rabbits, with ages
varying between 4 and 8 days, were infused intravenously with either 111
or 16.5 jig/kg/hr of DMSO. To test for significant time-dependent trends
the Page test was used followed by the HoIm's correction. To test for
dose-dependent effects, the deltas (value group 1—value group 2) were
computed and used as data for the Page test. DMSO exhibited a
dose-dependent increase in glomerular filtration rate (GFR), urine flow
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rate (Uf/kg), filtration fraction (FF) and renal vascular resistance (RVR)
(P < 0.00 1), in combination with a dose-dependent decrease in renal
blood flow (RBF) (P < 0.001). Furthermore, DMSO infusion resulted in
a significant dose-dependent increase in the fractional excretions of
sodium and chloride (FENa and FECI) (P < 0.001). Such low doses have
previously never been found to affect renal function. Since vasoactive
factors are hyperactive in the immature kidney, it was postulated that the
alteration of one of these factors, probably the inhibition of prostaglandin
synthesis, was responsible for the significant renal vasoconstriction. Inhi-
bition of the already scarcely available Na7K ATPase was postulated to
be responsible for the increase in FENa and FEd. Consequently this
agent should be used with caution in developmental studies.
